CooperCompanies reported fiscal Q2 2026 revenue of $1.082B, up 8% year over year, with 5% organic growth. GAAP EPS declined to $(0.40) due to a $271.6M litigation charge, while non-GAAP EPS rose 26% to $1.21. The company reaffirmed FY26 guidance, highlighted margin expansion on a non-GAAP basis, and advanced the CooperSurgical recall settlement, supporting stronger cash flow and ongoing buyback activity.
Investors may focus on non-GAAP margin resilience, robust free cash flow, and a meaningful buyback while GAAP results are skewed by a one-off charge; resolution of recall-related litigation reduces risk, potentially driving multiple expansion as guidance stays intact.
Long COO over a 6–12 month horizon on margin expansion, strong FCF, and recall resolution supporting upside.
Category: Earnings. Fits due to quarterly results, GAAP vs non-GAAP reconciliations, updated guidance, and litigation impact; emphasizes operating discipline and cash generation driving value.